Evergen and UiPath show how agentic AI tests process discipline in regulated industries

When Carlos Miranda’s team at Evergen began testing an AI agent to support donor tissue eligibility screening, the objective was clear – validate the technology before moving toward production. What emerged instead was a more uncomfortable finding – the testing process exposed weaknesses in the manual workflows the agent was meant to support.

Miranda explains:

We were seeing discrepancies between what the agent was identifying and what the human identified. When we went back and reviewed those, most of them – I would say about 90 percent or more – were either discrepancies because we didn’t have enough information in our documents to guide the agent to make the determination, or the human made an error. It was eye-opening for us to look back and say, this agent is already pointing out issues in our process, and this is only in test mode.

For Evergen, a regenerative medicine contract development and manufacturing ...